KaloBios Pharmaceuticals Inc. (HGEN)
(Delayed Data from OTC)
$1.15 USD
-0.07 (-6.07%)
Updated May 3, 2019 01:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HGEN 1.15 -0.07(-6.07%)
Will HGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HGEN
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
HGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates